Genomics of myelodysplastic/myeloproliferative neoplasm
Myelodysplastic/ Myeloproliferative neoplasms (MDS/MPN) demonstrate overlapping pathologic and molecular features of myelodysplastic (MDS) and myeloproliferative (MPN) neoplasms.
Myelodysplastic Syndromes (MDS)
2023 AAMDSIF Patient and Family Conference in Dallas, TX
Join patients, families and caregivers for the 2023 Dallas, TX Patient and Family Conference This event is chaired and organized by Dr. Taha Bat from UT Southwestern.
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study
Original Publication Date
Article Source
External Web Content
Key Points In MDS, health-related quality of life (HRQoL) was worse for vulnerable participants and those with worse prognosis. Lower-risk MDS was associated with better HRQoL, but this relationship was lost among the vulnerable. Health-related quality of life (HRQoL) and…
What is the IPSS-M for MDS?
Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Gail J. Roboz, M.D.
In this webinar, Dr. Gail Roboz discusses the Molecular International Prognostic Scoring System (IPSS-M) which is a newly developed risk stratification model for myelodysplastic syndromes (MDS) that expands on the original IPSS-R by including data on somatic oncogenic mutations…
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
Two articles in this week’s issue focus on the use of ipilimumab and decitabine decitabine: It works by reducing the amount of methylation in the body.